<DrugInformationSummary id="CDR0000798438"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about polatuzumab vedotin-piiq
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/polatuzumabvedotin-piiq">Polatuzumab Vedotin-piiq</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000695317">polatuzumab vedotin-piiq</TerminologyLink><GlossaryLink ref="CDR0000798457">polatuzumab vedotin</GlossaryLink><USBrandNames><USBrandName>Polivy</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>POH-lah-TOO-zoo-mab veh-DOH-tin</TermPronunciation><MediaLink ref="CDR0000798898" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000798899" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20a16ab2-f338-4abb-9dcd-254bd949a2bc&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Polatuzumab Vedotin-piiq</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20a16ab2-f338-4abb-9dcd-254bd949a2bc&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Polatuzumab vedotin-piiq
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000428286" dictionary="Cancer.gov" audience="Patient">Diffuse large B-cell lymphoma</GlossaryTermRef> (DLBCL).</Strong>  It is used:<ItemizedList Style="bullet" id="_6"><ListItem>With <GlossaryTermRef href="CDR0000045525" dictionary="Cancer.gov" audience="Patient">rituximab</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045253" dictionary="Cancer.gov" audience="Patient">cyclophosphamide</GlossaryTermRef>, <GlossaryTermRef href="CDR0000560140" dictionary="Cancer.gov" audience="Patient">doxorubicin hydrochloride</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045492" dictionary="Cancer.gov" audience="Patient">prednisone</GlossaryTermRef> as the first treatment in adults who have low-intermediate to high-risk DLBCL or high-grade <GlossaryTermRef href="CDR0000444967" dictionary="Cancer.gov" audience="Patient">B-cell lymphoma</GlossaryTermRef>.</ListItem><ListItem>With <GlossaryTermRef href="CDR0000386197" dictionary="Cancer.gov" audience="Patient">bendamustine hydrochloride</GlossaryTermRef> and rituximab in adults whose DLBCL has come back or has not gotten better after at least two other therapies.</ListItem></ItemizedList> </ListItem>
   </ItemizedList>
  <Para id="_5">Polatuzumab vedotin-piiq
         is also being studied in the treatment of other types of
         <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>.</Para>
 </Section><Section id="_About"><Title>More About Polatuzumab Vedotin-piiq</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/695317">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.27">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a619039.html">Polatuzumab Vedotin-piiq</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.28"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.29">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C104153">Find Clinical Trials for Polatuzumab Vedotin-piiq</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2019-06-25</DateFirstPublished><DateLastModified>2023-04-24</DateLastModified></DrugInformationSummary>
